NAPA, Calif., Nov. 7 (UPI) -- Senetek said Tuesday it has acquired the exclusive rights to technology that uses interference RNA to treat brain tumors.
The company said it has contracted with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan, Poland, for the exclusive rights to the anti-cancer technology, along with the exclusive rights to three compounds to treat skin aging.
The anti-cancer technology using RNA interference to treat brain tumors inhibits production of tenascin-C, which has been linked to the grade of malignancy of brain tumors.
The technology has already been used in treating a common type of brain tumor known as glioblastoma multiforme with "resounding success," the company said.
"The current options for patients with brain tumors consist of treatments such as surgery and chemotherapy and/or radiotherapy; which have an average survival time of only 8 to 10 months," said Frank Massino, CEO and chairman of Senetek. "This new technology works not only to prolong the survival of patients suffering from brain tumors, but possibly to cure them as well."